CN115466263A - Tricyclic compound and use thereof - Google Patents
Tricyclic compound and use thereof Download PDFInfo
- Publication number
- CN115466263A CN115466263A CN202210652494.6A CN202210652494A CN115466263A CN 115466263 A CN115466263 A CN 115466263A CN 202210652494 A CN202210652494 A CN 202210652494A CN 115466263 A CN115466263 A CN 115466263A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compound
- formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 108
- 150000003839 salts Chemical class 0.000 claims abstract description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 3
- -1 hydroxy, cyano, amino Chemical group 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 15
- 229910052805 deuterium Inorganic materials 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 101100421901 Caenorhabditis elegans sos-1 gene Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 abstract 1
- 102000057028 SOS1 Human genes 0.000 abstract 1
- 108700022176 SOS1 Proteins 0.000 abstract 1
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 abstract 1
- 101150100839 Sos1 gene Proteins 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 102000016914 ras Proteins Human genes 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100030708 GTPase KRas Human genes 0.000 description 4
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 102200006539 rs121913529 Human genes 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- ZSDPIQSHJSYDLJ-UHFFFAOYSA-N 2-amino-5-bromo-6-chloropyridine-3-carboxylic acid Chemical compound NC1=NC(Cl)=C(Br)C=C1C(O)=O ZSDPIQSHJSYDLJ-UHFFFAOYSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- GEBNAQNNXDZFLW-UHFFFAOYSA-N 6-bromo-7-chloro-2-methyl-3H-pyrido[2,3-d]pyrimidin-4-one Chemical compound CC(N1)=NC(N=C(C(Br)=C2)Cl)=C2C1=O GEBNAQNNXDZFLW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VHPJTQRGBIFUHQ-UHFFFAOYSA-N CC(N1)=NC(N2C(C(Br)=C3)=NN=C2)=C3C1=O Chemical compound CC(N1)=NC(N2C(C(Br)=C3)=NN=C2)=C3C1=O VHPJTQRGBIFUHQ-UHFFFAOYSA-N 0.000 description 2
- WEGLOYDTDILXDA-OAHLLOKOSA-N CNCc1ccccc1-c1csc(c1)[C@@H](C)Nc1nc(C)nc2cc(OC)c(OC)cc12 Chemical compound CNCc1ccccc1-c1csc(c1)[C@@H](C)Nc1nc(C)nc2cc(OC)c(OC)cc12 WEGLOYDTDILXDA-OAHLLOKOSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- RENBVEOCTVQABH-UHFFFAOYSA-N 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 RENBVEOCTVQABH-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- DOSGEBYQRMBTGS-UHFFFAOYSA-N 2-(3,6-dihydro-2h-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCOCC1 DOSGEBYQRMBTGS-UHFFFAOYSA-N 0.000 description 1
- INERBKPRIWEQRQ-UHFFFAOYSA-N 2-amino-6-chloropyridine-3-carboxylic acid Chemical compound NC1=NC(Cl)=CC=C1C(O)=O INERBKPRIWEQRQ-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- BYNSEGCAYWNMTP-UHFFFAOYSA-N 6-bromo-7-chloro-2-methylpyrido[2,3-d][1,3]oxazin-4-one Chemical compound CC(O1)=NC(N=C(C(Br)=C2)Cl)=C2C1=O BYNSEGCAYWNMTP-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- LMVWLMYIWIMIAX-NUBCRITNSA-N Cl.FC(C=1C(=C(C=CC=1)[C@@H](C)N)F)F Chemical compound Cl.FC(C=1C(=C(C=CC=1)[C@@H](C)N)F)F LMVWLMYIWIMIAX-NUBCRITNSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000713810 Rat sarcoma virus Species 0.000 description 1
- 229940126271 SOS1 inhibitor Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001334 alicyclic compounds Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000005959 oncogenic signaling Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 102000016731 rac GTP-Binding Proteins Human genes 0.000 description 1
- 108010092883 rac GTP-Binding Proteins Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 238000005533 tritiation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a tricyclic compound and application thereof, in particular to a compound shown in a formula (I) or pharmaceutically acceptable salt thereof,
Description
The invention requires the priority of the prior application with patent application number of 202110649480.4 entitled "tricyclic compound and application thereof" submitted to the intellectual property office of China in 2021, 6 months and 10 days. The entire contents of the above-mentioned prior application are incorporated herein by reference.
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a tricyclic compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the tricyclic compound or the pharmaceutically acceptable salt thereof, and application of the tricyclic compound or the pharmaceutically acceptable salt thereof as an SOS1 inhibitor in prevention or treatment of related diseases.
Background
RAS family proteins including KRAS (V-Ki-RAS 2 Kirsten rat sarcoma virus oncogene homolog), NRAS (neuroblastoma RAS virus oncogene homolog), HRAS (Harvey murine sarcoma virus oncogene), and the like, are small gtpases present in cells in either GTP-bound or GDP-bound states (McCormick et al, j.mol.med. (Berl.) 2016,94 (3): 253-8 nimnual et al, sci.stke.,2002 (145): pe 36).
RAS family proteins play an important role in human cancers. Tumors caused by RAS protein mutations account for 20-30% of all tumors in humans and are considered as tumorigenic drivers, particularly in lung, colorectal and pancreatic cancers (Malumbres & Barbacid 2002Nature Reviews Cancer, pylayeva-Gupta et al, 2011Nature Reviews Cancer).
SOS1 (son of seven homology 1) protein is a regulatory protein widely expressed in cells, and plays an important role in regulating RAS and RAC signal transduction pathways in cells as a guanine nucleotide exchange factor of RAS and RAC proteins. SOS1 has two binding sites for RAS family proteins: a catalytic site that binds a GDP-bound RAS family protein to facilitate guanine nucleotide exchange; an allosteric site that binds to a GTP-bound RAS family protein, which results in a further increase in the catalytic GEF function of SOS1 (Freedman et al, proc. Natl.Acad.Sci.USA.,2006,103 (4): 16692-7, pierre et al, biochem. Pharmacol.,2011,82 (9): 1049-56). Published data indicate that SOS1 is involved in mutant KRAS activation and oncogenic signaling in cancer (Jeng et al, nat. Commun.,2012, 3. Consumption of SOS1 levels decreased the proliferation rate and survival of tumor cells carrying KRAS mutations, whereas no effect was observed in KRAS wild-type cell lines. The effect of loss of SOS1 was not compensated by SOS1 with the introduction of a catalytic site mutation, further demonstrating the important role of SOS1 GEF activity in KRAS mutant cancer cells.
In recent decades, RAS family protein-SOS 1 protein interactions have been increasingly studied. Small activating molecules have been identified that bind to the lipophilic pocket of SOS1 in close proximity to the RAS binding site (Burns et al, proc. Natl. Acad. Sci.2014,111 (9): 3401-6). However, the binding of these molecules appears to result in an increase in nucleotide exchanges, thereby activating, rather than inactivating, the RAS.
Although some small molecule inhibitors of SOS1 are reported in the prior literature (for example, patent document WO2018/115380 A1), a large number of patients still cannot obtain satisfactory clinical treatment effects, so that there is still a need to develop SOS1 inhibitors with better activity, selectivity and safety.
Disclosure of Invention
The invention provides a compound shown in a formula (I) and a pharmaceutically acceptable salt thereof. These compounds can inhibit the activity of SOS1, thereby affecting biological functions.
The invention provides a compound shown in a formula (I) or a pharmaceutically acceptable salt thereof,
wherein,
x is selected from CH or N;
y is selected from CH or N;
z is selected from CH or N;
l is selected from the group consisting of a bond, NR 6 Or O;
R 6 is selected from H orC 1 -C 6 An alkyl group;
R 1 selected from H, halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 1 -C 3 Haloalkyl, C 1 -C 3 Deuterated alkyl, -O-C 1 -C 6 Alkyl or C 3 -C 6 A cycloalkyl group;
R 2 is selected from C 3 -C 10 Cycloalkyl, C 6 -C 10 Aryl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl, said C 3 -C 10 Cycloalkyl radical, C 6 -C 10 Aryl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 2b And/or R 2c Substitution;
R 2b independently selected from halogen, cyano, -OR 2c 、-N(R 2c ) 2 、-C(O)R 2c 、-C(O)N(R 2c ) 2 、-C(O)OR 2c 、-S(O) 2 R 2c 、-S(O) 2 N(R 2c ) 2 、-NHC(O)R 2c or-N (C) 1 -C 3 Alkyl) C (O) R 2c ;
Each R 2c Independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl, C 1 -C 6 Alkyl radical, C 3 -C 10 Cycloalkyl, C 6 -C 10 Aryl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl, said C 1 -C 6 Alkyl radical, C 3 -C 10 Cycloalkyl radical, C 6 -C 10 Aryl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 2d Substitution;
R 2d selected from independently halogen, hydroxy, cyano, amino, -C (O) R 2f 、-C(O)N(R 2f ) 2 、-C(O)OR 2f 、-S(O) 2 R 2f 、-S(O) 2 N(R 2f ) 2 、-N(C 1 -C 3 Alkyl) R 2f 、-NHC(O)R 2f or-N (C) 1 -C 3 Alkyl) C (O) R 2f ;
Each R 2f Independently selected from H or C 1 -C 6 An alkyl group;
R 3 、R 4 independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl, C 1 -C 6 Alkyl or C 1 -C 3 A haloalkyl group;
R 5 selected from halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, -O- (4-7 membered heterocyclyl), -S (O) 2 -C 1 -C 3 Alkyl, -P (O) (R) 5b ) 2 、-C(O)R 5b 、-C(O)N(R 5b ) 2 、-C(O)OR 5b 、4-7 membered heterocyclic group or 5-10 membered heteroaryl group, said C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, -O- (4-7 membered heterocyclyl), -S (O) 2 -C 1 -C 3 Alkyl, 4-7 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 5a Substitution;
R 5a selected from halogen, hydroxy, cyano or amino;
each R 5b Independently selected from H or C 1 -C 6 An alkyl group;
n is selected from 0, 1,2,3 or 4;
ring A is selected from C 6 -C 10 Aryl, 5-10 membered heterocyclyl or 5-10 membered heteroaryl.
In some embodiments, R 1 Selected from H, C 1 -C 6 Alkyl or C 1 -C 3 A deuterated alkyl group.
In some embodiments, R 1 Selected from H, C 1 -C 3 Alkyl or C 1 -C 3 A deuterated alkyl group.
In some embodiments, R 1 Selected from H, CH 3 Or CD 3 。
In some embodiments, R 1 Is selected from CH 3 。
In some embodiments, R 2 Selected from 3-10 membered heterocyclyl or 5-10 membered heteroaryl, said 3-10 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 2b And/or R 2c And (4) substitution.
In some embodiments, R 2 Selected from 4-6 membered heterocyclyl or 5-6 membered heteroaryl, said 4-6 membered heterocyclyl or 5-6 membered heteroaryl optionally substituted with R 2b And/or R 2c And (4) substitution.
In some embodiments, R 2 Selected from the following groups: piperidinyl, dihydropyranyl, tetrahydropyridinyl, azetidinyl, morpholinyl or pyrazolyl optionally substituted by R 2b And/or R 2c And (4) substitution.
in some embodiments, R 2b Independently selected from halogen, cyano, -OR 2c 、-N(R 2c ) 2 、-C(O)R 2c 、-C(O)N(R 2c ) 2 、-C(O)OR 2c 、-NHC(O)R 2c or-N (C-C) 3 Alkyl) C (O) R 2c 。
In some embodiments, R 2b Independently selected from-OR 2c 、-C(O)R 2c or-C (O) N (R) 2c ) 2 。
In some embodiments, R 2b Independently selected from-OH, -O-CH 3 、-C(O)CH 3 、-C(O)CD 3 or-C (O) NHCH 3 。
In some embodiments, R 2b Selected from the group consisting of-C (O) R 2c 。
In some embodiments, each R is 2c Independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl, C 1 -C 6 Alkyl radical, C 3 -C 10 Cycloalkyl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl, said C 1 -C 6 Alkyl radical, C 3 -C 10 Cycloalkyl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 2d And (4) substitution.
In some embodiments, each R is 2c Independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl or C 1 -C 6 Alkyl radical, said C 1 -C 6 Alkyl is optionally substituted by R 2d And (4) substitution.
In some embodiments, each R is 2c Independently selected from H, deuterium, CD 3 Or CH 3 。
In some embodiments, R 2c Is selected from C 1 -C 6 An alkyl group.
In some embodiments, R 3 、R 4 Independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl or C 1 -C 6 An alkyl group.
In some embodiments, R 3 、R 4 Independently selected from H, deuterium, CH 3 Or CD 3 。
In some embodiments, R 3 Selected from H or deuterium, R 4 Is selected from CH 3 Or CD 3 。
In some embodiments, R 3 Selected from H, R 4 Is selected from CH 3 。
In some embodiments, R 5 Selected from halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, -O-C 1 -C 6 Alkyl, -S (O) 2 -C 1 -C 3 Alkyl, -P (O) (R) 5b ) 2 、4-7 membered heterocyclic group or 5-10 membered heteroaryl group, said C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, -O-C 1 -C 6 Alkyl, -S (O) 2 -C 1 -C 3 Alkyl, 4-7 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 5a And (4) substitution.
In some embodiments, R 5 Selected from halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl, -O-C 1 -C 6 Alkyl, -S (O) 2 -C 1 -C 3 Alkyl, -P (O) (R) 5b ) 2 、Or 4-7 membered heterocyclic group, said C 1 -C 6 Alkyl, -O-C 1 -C 6 Alkyl, -S (O) 2 -C 1 -C 3 Alkyl or 4-7 membered heterocyclyl is optionally substituted by R 5a And (4) substitution.
In some embodiments, R 5 Selected from halogen, amino, C 1 -C 6 Alkyl, -S (O) 2 -C 1 -C 3 Alkyl, -P (O) (R) 5b ) 2 OrSaid C is 1 -C 6 Alkyl or-S (O) 2 -C 1 -C 3 Alkyl is optionally substituted by R 5a And (4) substitution.
In some embodiments, R 5 Is selected from F and CH 3 Amino, -S (O) 2 -CH 3 or-P (O) (CH) 3 ) 2 Said CH 3 or-S (O) 2 -CH 3 Optionally substituted with R 5a And (4) substitution.
In some embodiments, R 5 Selected from halogen, amino or C 1 -C 6 Alkyl radical, said C 1 -C 6 Alkyl is optionally substituted by R 5a And (4) substitution.
In some embodiments, R 5 Selected from F and CH 3 Or amino group, said CH 3 Optionally substituted by R 5a And (4) substitution.
In some embodiments, R 5 Selected from halogen or C 1 -C 6 Alkyl radical, said C 1 -C 6 Alkyl is optionally substitutedIs covered with R 5a And (4) substitution.
In some embodiments, R 5 Is selected from F or CH 3 Said CH 3 Optionally substituted by R 5a And (4) substitution.
In some embodiments, R 5 Selected from F or CHF 2 。
In some embodiments, R 5a Selected from halogens.
In some embodiments, n is selected from 0, 1 or 2.
In some embodiments, n is selected from 2.
In some embodiments, ring a is selected from C 6-10 Aryl, 9-10 membered heterocyclyl or 9-10 membered heteroaryl.
In some embodiments, ring a is selected from C 6-10 And (3) an aryl group.
In some embodiments, ring a is selected from phenyl.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (II) or a pharmaceutically acceptable salt thereof:
wherein, ring A, L, R 1 ,R 2 ,R 3 ,R 4 ,R 5 And n is as defined above.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (III) or a pharmaceutically acceptable salt thereof,
wherein, ring A, L, R 1 ,R 2 ,R 3 ,R 4 ,R 5 And n is as defined above.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (IV) or a pharmaceutically acceptable salt thereof,
wherein, ring A, L, R 1 ,R 2 ,R 3 ,R 4 ,R 5 And n is as defined above.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (V) or a pharmaceutically acceptable salt thereof,
wherein, ring A, L, R 1 ,R 2 ,R 3 ,R 4 ,R 5 And n is as defined above.
In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt thereof, is selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
further, the invention also provides a pharmaceutical composition, which comprises the compound shown in the formula (I) or pharmaceutically acceptable salt thereof and pharmaceutically acceptable auxiliary materials.
Further, the invention relates to application of the compound shown in the formula (I) or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in preparing a medicament for preventing or treating SOS1 related diseases.
Further, the invention relates to application of the compound shown as the formula (I) or pharmaceutically acceptable salts thereof or a pharmaceutical composition thereof in preventing or treating SOS1 related diseases.
Further, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for preventing or treating SOS 1-related diseases.
The present invention also relates to a method of treating SOS 1-related disorders comprising administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as described herein.
Further, the SOS 1-associated disease is selected from cancer.
Unless otherwise indicated, the terms used in the present invention have the following meanings, and the group and term definitions described in the present invention, including definitions thereof as examples, exemplary definitions, preferred definitions, definitions described in tables, definitions of specific compounds in examples, and the like, may be arbitrarily combined and combined with each other. A particular term should not be considered as ambiguous or unclear without special definition, but rather construed according to ordinary meaning in the art. When a trade name appears herein, it is intended to refer to its corresponding commodity or its active ingredient.
The illustrations of racemic or enantiomerically pure compounds herein are from Maehr, j.chem.ed.1985, 62. Using wedge and virtual wedge keys, unless otherwise indicatedRepresenting an absolute configuration of a solid center, with black solid and dotted bondsIndicates the relative configuration of a stereocenter (e.g., cis-trans configuration of an alicyclic compound).
The term "tautomer" refers to an isomer of a functional group resulting from the rapid movement of an atom in a molecule at two positions. The compounds of the invention may exhibit tautomerism. Tautomeric compounds may exist in two or more interconvertible species. Tautomers generally exist in equilibrium, and attempts to isolate a single tautomer usually result in a mixture whose physicochemical properties are consistent with the mixture of the compounds. The position of equilibrium depends on the chemical properties within the molecule. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the keto form predominates; whereas in phenol the enol type predominates. The present invention encompasses all tautomeric forms of the compounds.
The term "stereoisomer" refers to isomers resulting from the different arrangement of atoms in a molecule, including cis-trans isomers, enantiomers, and diastereomers.
The compounds of the present invention may have asymmetric atoms such as carbon atom, sulfur atom, nitrogen atom, phosphorus atom or asymmetric double bond, and thus the compounds of the present invention may exist in a specific geometric or stereoisomeric form. The particular geometric or stereoisomeric forms may be the cis and trans isomers, the E and Z geometric isomers, the (-) -and (+) -enantiomers, (R) -and (S) -enantiomers, diastereomers, (D) -isomers, (L) -isomers, as well as racemic or other mixtures thereof, e.g., enantiomerically or diastereomerically enriched mixtures, all of which, as well as mixtures thereof, are within the definition of the compounds of the present invention. The presence of additional asymmetric carbon, sulfur, nitrogen or phosphorus atoms in substituents such as alkyl groups is also within the definition of the compounds of the invention as regards all such isomers and mixtures thereof. The compounds of the invention containing asymmetric atoms can be isolated in optically pure form or in racemic form, the optically pure form can be resolved from a racemic mixture, or synthesized by using chiral starting materials or chiral reagents.
The term "substituted" means that any one or more hydrogen atoms on a particular atom is replaced with a substituent, so long as the valence of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (i.e = O), meaning that two hydrogen atoms are substituted, oxo does not occur on the aromatic group.
The terms "optional" or "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, ethyl is "optionally" substituted with halo, meaning that ethyl may be unsubstituted (CH) 2 CH 3 ) Monosubstituted (CH) 2 CH 2 F、CH 2 CH 2 Cl, etc.), polysubstituted (CHFCH) 2 F、CH 2 CHF 2 、CHFCH 2 Cl、CH 2 CHCl 2 Etc.) or completely substituted (CF) 2 CF 3 、CF 2 CCl 3 、CCl 2 CCl 3 Etc.). It will be appreciated by those skilled in the art that any group containing one or more substituents will not incorporate any substitution or substitution patterns which are sterically impossible and/or synthetically impossible.
When any variable (e.g. R) a 、R b ) When a compound occurs more than one time in its composition or structure, its definition in each case is independent. For example, if a group is substituted by 2R b Substituted, then each R b There are separate options.
When the number of one linking group is 0, e.g. - (CH) 2 ) 0 -, denotes that the linking group is a bond.
When one of the variables is selected from a chemical bond or is absent, it indicates that the two groups to which it is attached are directly linked, e.g., L in A-L-Z represents a bond, indicating that the structure is actually A-Z.
When referring to a linking group herein, the direction of attachment is arbitrary unless it is indicated. For example as a structural elementL in (1) 1 Is selected from "C 1 -C 3 alkylene-O', when L is 1 The rings Q and R can be connected in the direction from left to right 1 Form "Ring Q-C 1 -C 3 alkylene-O-R 1 ", the rings Q and R may be connected in the right-to-left direction 1 Form "ring Q-O-C 1 -C 3 alkylene-R 1 ”。
When a substituent's bond is cross-linked to two atoms on a ring, such substituent may be bonded to any atom on the ring. For example, a structural unitRepresents R 5 The substitution may occur at any position on the phenyl ring.
Herein C m -C n Refers to having an integer number of carbon atoms in the range of m-n. For example "C 1 -C 10 By "is meant that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, or 10 carbon atoms.
The term "C 1 -C 3 Haloalkyl "comprises monohalogenated C 1 -C 3 Alkyl or polyhalogenated C 1 -C 3 Specific examples of alkyl groups include, but are not limited to, trifluoromethyl, 2-trichloroethyl, or 3-fluoropropyl, and the like.
The term "C 1 -C 3 Deuterated alkyl "C containing mono-deuteration 1 -C 3 Alkyl or deuterated C 1 -C 3 Alkyl, specific examples include but are not limited to CD 3 、CH 2 CD 3 And so on.
The term "alkyl" refers to a group of formula C n H 2n+1 The alkyl group may be linear or branched. The term "C 1 -C 10 Alkyl "is understood to mean a straight-chain or branched saturated hydrocarbon radical having 1,2,3, 4,5, 6,7,8, 9 or 10 carbon atoms. Specific examples of the alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-ethylpropyl, 1, 2-dimethylpropyl, neopentyl, 1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 2, 3-dimethylbutyl, 1, 3-dimethylbutyl or 1, 2-dimethylbutyl, etc.; the term "C 1 -C 6 Alkyl "is understood to mean an alkyl group having from 1 to 6 carbon atoms, specific examples including, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl and the like. The term "C 1 -C 3 Alkyl "is understood to mean a straight-chain or branched saturated alkyl group having from 1 to 3 carbon atoms. Said "C" is 1 -C 10 Alkyl groups "may contain" C 1 -C 6 Alkyl "or" C 1 -C 3 Alkyl radicals ", said" C 1 -C 6 The alkyl group "may further comprise" C 1 -C 3 Alkyl groups ".
The term "cycloalkyl" refers to a carbon ring that is fully saturated and exists as a single ring, a bicyclic ring, a bridged ring, or a spiro ring, among others. Unless otherwise indicated, the carbocycle is typically a 3 to 10 membered ring. The term "C 3 -C 10 Cycloalkyl "is understood to mean a saturated monocyclic, bicyclic, spirocyclic or bridged ring having from 3 to 10 carbon atoms. Specific examples of such cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl (bicyclo [2.2.1 ] s)]Heptyl), bicyclo [2.2.2]Octyl, adamantyl, spiro [4.5 ]]Decyl, and the like. The term "C 3 -C 10 Cycloalkyl "may contain" C 3 -C 6 Cycloalkyl radical ", the term" C 3 -C 6 Cycloalkyl "is understood to mean a saturated monocyclic or bicyclic hydrocarbon ring having from 3 to 6 carbon atoms, specific examples including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and the like.
The term "heterocyclyl" refers to a fully or partially saturated (not heteroaromatic with aromatic character as a whole) monocyclic, fused, spiro or bridged ring group containing 1 to 5 heteroatoms or heteroatom groups in ring atoms (i.e., containing heteroatoms)The "heteroatom or heteroatom group" includes, but is not limited to, a nitrogen atom (N), an oxygen atom (O), a sulfur atom (S), a phosphorus atom (P), a boron atom (B), -S (= O) 2 -、-S(=O)-、-P(=O) 2 -, -P (= O) -, -NH-, -S (= O) (= NH) -, and-C (= O) NH-, or-NHC (= O) NH-, or the like. The term "3-10 membered heterocyclyl" refers to heterocyclyl groups having a ring atom number of 3,4, 5,6,7,8, 9 or 10 and having 1-5 heteroatoms or groups of heteroatoms in the ring atoms independently selected from those described above. "3-10 membered heterocyclic group" includes "4-7 membered heterocyclic group", wherein specific examples of the 4 membered heterocyclic group include, but are not limited to, azetidinyl or oxetanyl; specific examples of 5-membered heterocyclic groups include, but are not limited to, tetrahydrofuranyl, dioxolyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, 4, 5-dihydrooxazolyl, or 2, 5-dihydro-1H-pyrrolyl; specific examples of 6-membered heterocyclyl include, but are not limited to, tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, tetrahydropyridinyl, or 4H- [1,3,4]Thiadiazinyl; specific examples of 7-membered heterocyclic groups include, but are not limited to, diazepanyl. The heterocyclic group may also be a bicyclic group, wherein specific examples of the 5,5-membered bicyclic group include, but are not limited to, hexahydrocyclopenta [ c ] group]Pyrrol-2 (1H) -yl; specific examples of 5,6-membered bicyclic groups include, but are not limited to, hexahydropyrrolo [1,2-a ]]Pyrazin-2 (1H) -yl, 5,6,7,8-tetrahydro- [1,2,4]Triazolo [4,3-a]Pyrazinyl or 5,6,7,8-tetrahydroimidazo [1,5-a ]]A pyrazinyl group. Optionally, the heterocyclic group may be a benzo-fused ring group of the above-mentioned 4-7 membered heterocyclic group, and specific examples include, but are not limited to, dihydroisoquinolinyl and the like. "4-to 10-membered heterocyclic group" may include ranges of "5-to 10-membered heterocyclic group", "4-to 7-membered heterocyclic group", "5-to 6-membered heterocyclic group", "6-to 8-membered heterocyclic group", "4-to 10-membered heterocycloalkyl group", "5-to 10-membered heterocycloalkyl group", "4-to 7-membered heterocycloalkyl group", "5-to 6-membered heterocycloalkyl group", "6-to 8-membered heterocycloalkyl group" and the like, and "4-to 7-membered heterocyclic group" may further include ranges of "4-to 6-membered heterocyclic group", "5-to 6-membered heterocyclic group", "4-to 7-membered heterocycloalkyl group", "4-to 6-membered heterocycloalkyl group", "5-to 6-membered heterocycloalkyl group" and the like. Although some bicyclic heterocyclic groups of the present invention contain, in part, a benzene ring or a heterocycleAromatic rings, but the heterocyclic group as a whole is still non-aromatic.
The term "aryl" refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated pi-electron system. The aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms. The term "C 6 -C 20 Aryl "is understood to mean aryl having from 6 to 20 carbon atoms. In particular a ring having 6 carbon atoms ("C) 6 Aryl "), such as phenyl; or a ring having 9 carbon atoms ("C) 9 Aryl "), such as indanyl or indenyl; or a ring having 10 carbon atoms ("C) 10 Aryl), such as tetralinyl, dihydronaphthyl, or naphthyl; or a ring having 13 carbon atoms ("C) 13 Aryl "), such as fluorenyl; or a ring having 14 carbon atoms ("C) 14 Aryl), such as anthracyl. The term "C 6 -C 10 Aryl "is understood to be an aryl group having from 6 to 10 carbon atoms. In particular a ring having 6 carbon atoms ("C) 6 Aryl "), such as phenyl; or a ring having 9 carbon atoms ("C) 9 Aryl "), such as indanyl or indenyl; or a ring having 10 carbon atoms ("C) 10 Aryl), such as tetralinyl, dihydronaphthyl, or naphthyl. The term "C 6 -C 20 Aryl "may contain" C 6 -C 10 Aryl radicals "
The term "heteroaryl" refers to a monocyclic or fused polycyclic aromatic ring system containing at least one ring atom selected from N, O, S, the remaining ring atoms being C. The term "5-to 10-membered heteroaryl" is understood to include monocyclic or bicyclic aromatic ring systems: it has 5,6,7,8, 9 or 10 ring atoms, in particular 5 or 6 or 9 or 10 ring atoms, and it contains 1 to 5, preferably 1 to 3 heteroatoms independently selected from N, O and S. In particular, heteroaryl is selected from thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl or thiadiazolyl and the like and their benzo derivatives, such as benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl or isoindolyl and the like; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like, and benzo derivatives thereof, such as quinolyl, quinazolinyl, isoquinolyl, and the like; or azocinyl, indolizinyl, purinyl and the like and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl or phenoxazinyl, and the like. The term "5-6 membered heteroaryl" refers to an aromatic ring system having 5 or 6 ring atoms and which contains 1-3, preferably 1-2 heteroatoms independently selected from N, O and S.
The term "halo" or "halogen" refers to fluorine, chlorine, bromine or iodine.
The term "hydroxy" refers to an-OH group.
The term "cyano" refers to the group — CN.
The term "amino" refers to the group-NH 2 A group.
The term "nitro" means-NO 2 A group.
The term "therapeutically effective amount" refers to an amount of a compound of the invention that (i) treats a particular disease, condition, or disorder, (ii) reduces, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein. The amount of a compound of the present invention that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art with their own knowledge and this disclosure.
The term "pharmaceutically acceptable" is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The term "pharmaceutically acceptable salt" refers to salts of pharmaceutically acceptable acids or bases, including salts of compounds with inorganic or organic acids, and salts of compounds with inorganic or organic bases.
The term "pharmaceutical composition" refers to a mixture of one or more compounds of the invention or salts thereof with pharmaceutically acceptable excipients. The purpose of the pharmaceutical composition is to facilitate administration of the compounds of the invention to an organism.
The term "pharmaceutically acceptable adjuvants" refers to those adjuvants which do not have a significant irritating effect on the organism and do not impair the biological activity and properties of the active compound. Suitable adjuvants are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and/or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.
The word "comprising" or "comprises" and variations thereof such as "comprises" or "comprising", will be understood to have an open, non-exclusive meaning, i.e., "including but not limited to".
The invention also includes isotopically-labeled compounds of the present invention, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine, such as respectively 2 H、 3 H、 11 C、 13 C、 14 C、 13 N、 15 N、 15 O、 17 O、 18 O、 31 P、 32 P、 35 S、 18 F、 123 I、 125 I and 36 cl, and the like.
Certain isotopically-labelled compounds of the invention (e.g. by 3 H and 14 c-label) can be used in compound and/or substrate tissue distribution assays. Tritiated (i.e. by tritiation) 3 H) And carbon-14 (i.e. 14 C) Isotopes are particularly preferred for their ease of preparation and detectability. Positron emitting isotopes, such as 15 O、 13 N、 11 C and 18 f for positronsEmission Tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the schemes and/or in the examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
The pharmaceutical composition of the present invention can be prepared by combining the compound of the present invention with suitable pharmaceutically acceptable excipients, and can be formulated, for example, into solid, semisolid, liquid or gaseous preparations such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres, aerosols, and the like.
Typical routes of administration of the compounds of the present invention or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, intravenous administration.
The pharmaceutical compositions of the present invention may be manufactured by methods well known in the art, such as conventional mixing, dissolving, granulating, emulsifying, lyophilizing, and the like.
In some embodiments, the pharmaceutical composition is in an oral form. For oral administration, the pharmaceutical compositions may be formulated by mixing the active compounds with pharmaceutically acceptable excipients well known in the art. These adjuvants enable the compounds of the present invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, slurries, suspensions and the like, for oral administration to a patient.
Solid oral compositions may be prepared by conventional mixing, filling or tableting methods. For example, it can be obtained by the following method: the active compounds are mixed with solid adjuvants, optionally the mixture obtained is milled, if desired with further suitable adjuvants, and the mixture is then processed to granules, to give tablets or dragee cores. Suitable excipients include, but are not limited to: binders, diluents, disintegrants, lubricants, glidants or flavoring agents, and the like.
The pharmaceutical compositions may also be adapted for parenteral administration, as sterile solutions, suspensions or lyophilized products in suitable unit dosage forms.
In all methods of administration of the compounds of general formula (I) described herein, the daily dose is from 0.01mg/kg to 200mg/kg body weight, preferably from 0.05mg/kg to 50mg/kg body weight, more preferably from 0.1mg/kg to 30mg/kg body weight, in single or divided doses.
Detailed Description
The following examples illustrate the technical solutions of the present invention in detail, but the scope of the present invention includes but is not limited thereto.
The structure of the compounds is determined by Nuclear Magnetic Resonance (NMR) and/or Mass Spectrometry (MS). NMR shift in units of 10 -6 (ppm). Solvents for NMR determination are deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol and the like, and internal standard is Tetramethylsilane (TMS); ' IC 50 "half inhibitory concentration" means the concentration at which half of the maximum inhibitory effect is achieved.
Abbreviation:
NBS: n-bromosuccinimide; DMF: n, N-dimethylformamide; THF: tetrahydrofuran; ethanol: ethanol; pyAOP: triazolo [4,5-b]Pyridine-3-oxy) tri-1-pyrrolidinylhexafluorophosphate; DBU 1, 8-diazabicyclo [5.4.0]-7-undecene; pd (dppf) Cl 2 1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride; dioxane, dioxane; formic acid: formic acid; pd/C: palladium on carbon; acOH: acetic acid; methanol: methanol; NH (NH) 2 NH 2 Hydrazine hydrate.
Example 1: (R) -N- (1- (3- (difluoromethyl) -2-fluorophenyl) ethyl) -6- (3, 6-dihydro-2H-pyran-4-yl) -2-methyl- [1,2,4] triazolo [4',3':1,6] pyrido [2,3-d ] pyrimidin-4-amine
Step 1: synthesis of 2-amino-5-bromo-6-chloropyridine-3-carboxylic acid
2-amino-6-chloropyridine-3-carboxylic acid (25.0 g) was dissolved in 150mL of N, N-dimethylformamide, and N-bromosuccinimide (28.4 g) was added in portions, and the reaction was completed after heating to 70 ℃ and stirring for 2 hours. The reaction mixture was cooled to room temperature, poured into 500mL of ice-water mixture, filtered, the filter cake was washed three times with water and the filter cake was dried to give the title compound.
Step 2: synthesis of 6-bromo-7-chloro-2-methyl-pyrido [2,3-d ] [1,3] oxazin-4-one
2-amino-5-bromo-6-chloropyridine-3-carboxylic acid (36.0 g) was dissolved in 500mL of acetic anhydride, heated to 130 ℃ and stirred for 36 hours, after completion of the reaction, the reaction mixture was cooled to room temperature, concentrated and dried, and then directly fed to the next step.
And 3, step 3: synthesis of 6-bromo-7-chloro-2-methyl-3H-pyrido [2,3-d ] pyrimidin-4-one
And (3) dissolving the crude product obtained in the step 2 in 1L of tetrahydrofuran, dropwise adding ammonia methanol (7.0 mol/L,415 mL) into the reaction solution at the temperature of-30 ℃, and after dropwise adding, heating the reaction system to room temperature to react for 12 hours and then finishing the reaction. Pouring the reaction liquid into 1L of ice water, adding 4N diluted hydrochloric acid to adjust the pH value to 8-9, separating out light yellow solid, filtering, washing a filter cake with water for three times, drying, and then adding petroleum ether: ethyl acetate =3:1 (V: V) slurried and purified to give the title compound.
And 4, step 4: synthesis of 6-bromo-7-hydrazino-2-methylpyrido [2,3-d ] pyrimidin-4 (3H) -one
6-bromo-7-chloro-2-methyl-3H-pyrido [2,3-d ] pyrimidin-4-one (1.10 g) and hydrazine hydrate (927 ul) were dissolved in 10ml of ethanol, and after the reaction was completed with stirring at 70 ℃ for 3 hours, the reaction was filtered, the filter cake was washed with ethanol, and the filter cake was dried to give the title compound.
And 5: synthesis of 6-bromo-2-methyl- [1,2,4] triazolo [4',3':1,6] pyrido [2,3-d ] pyrimidin-4 (3H) -one
6-bromo-7-hydrazino-2-methylpyrido [2,3-d ] pyrimidin-4 (3H) -one (990 mg) was dissolved in 12ml of formic acid, and the reaction was completed at 100 ℃ for 4 hours, followed by concentration under reduced pressure to obtain the title compound.
Step 6: synthesis of (R) -6-bromo-N- (1- (3- (difluoromethyl) -2-fluorophenyl) ethyl) -2-methyl- [1,2,4] triazolo [4',3':1,6] pyrido [2,3-d ] pyrimidin-4-amine
6-bromo-2-methyl- [1,2,4] triazolo [4',3':1,6] pyrido [2,3-d ] pyrimidin-4 (3H) -one (200 mg), (3H-1, 2, 3-triazolo [4,5-b ] pyridin-3-yloxy) tri-1-pyrrolidinyl hexafluorophosphate (558 mg) was dissolved in 5ml of N, N-dimethylformamide, and 1, 8-diazabicyclo [5.4.0] -7-undecene (320 uL) was added, followed by stirring at room temperature for 30 minutes, followed by addition of (R) -1- (3- (difluoromethyl) -2-fluorophenyl) ethane-1-amine hydrochloride (193 mg) and reaction at room temperature overnight. After the reaction, ethyl acetate is added for dilution, water washing, saturated salt water washing, organic phase anhydrous sodium sulfate drying, filtration, concentration and column chromatography (petroleum ether/ethyl acetate gradient elution) are carried out to obtain the title compound.
And 7: synthesis of (R) -N- (1- (3- (difluoromethyl) -2-fluorophenyl) ethyl) -6- (3, 6-dihydro-2H-pyran-4-yl) -2-methyl- [1,2,4] triazolo [4',3':1,6] pyrido [2,3-d ] pyrimidin-4-amine
Reacting (R) -6-bromo-N- (1- (3- (difluoromethyl) -2-fluorophenyl) ethyl) -2-methyl- [1,2,4] triazolo [4',3':1,6] pyridine [2,3-d ] pyrimidin-4-amine (100 mg), 3, 6-dihydro-2H-pyran-4-boronic acid pinacol ester (69.9 mg), [1,1' -bis (diphenylphosphino) ferrocene ] palladium dichloride (16.2 mg), sodium carbonate (47.0 mg) dissolved in 2mL dioxane and 0.5mL water, argon replaced, and stirred at 100 ℃ for 2 hours. After the reaction, ethyl acetate is added for dilution, water washing, saturated salt water washing, organic phase anhydrous sodium sulfate drying, filtration, concentration and column chromatography (petroleum ether/ethyl acetate gradient elution) are carried out to obtain the title compound.
1 H NMR(400MHz,DMSO-d 6 )δ H 9.59(s,1H),8.78(d,J=7.2Hz,1H),8.06(s,1H),7.74-7.66(m,2H),7.52(t,J=7.1Hz,1H),7.32(t,J=7.7Hz,1H),7.25(t,J=54.4Hz,1H),5.83(p,J=7.0Hz,1H),4.40-4.38(m,2H),3.95(t,J=5.5Hz,2H),2.78-2.61(m,2H),2.45(s,3H),1.64(d,J=7.1Hz,3H).
LC/MS(m/z,MH + ):455.2.
Example 2: (R) -1- (4- (4- ((1- (3- (difluoromethyl) -2-fluorophenyl) ethyl) amino) -2-methyl- [1,2,4] triazolo [4',3':1,6] pyrido [2,3-d ] pyrimidin-6-yl) piperidin-1-yl) ethan-1-one
Step 1: synthesis of (R) -1- (4- ((1- (3- (difluoromethyl) -2-fluorophenyl) ethyl) amino) -2-methyl- [1,2,4] triazolo [4',3':1,6] pyrido [2,3-d ] pyrimidin-6-yl) -3, 6-dihydropyridin-1 (2H) -yl) ethan-1-one
Reacting (R) -6-bromo-N- (1- (3- (difluoromethyl) -2-fluorophenyl) ethyl) -2-methyl- [1,2,4] triazolo [4',3":1,6] pyridine [2,3-d ] pyrimidin-4-amine (100 mg), 1-acetyl-5, 6-dihydro-2H-pyridine-4-boronic acid pinacol ester (83.6 mg), [1,1' -bis (diphenylphosphino) ferrocene ] dichloropalladium (16.2 mg), sodium carbonate (47.0 mg) dissolved in 2mL dioxane and 0.5mL water, argon replaced, and stirred at 100 ℃ for 2 hours. After the reaction, ethyl acetate is added for dilution, water washing, saturated salt water washing, organic phase anhydrous sodium sulfate drying, filtration, concentration and column chromatography (petroleum ether/ethyl acetate gradient elution) are carried out to obtain the title compound.
And 2, step: synthesis of (R) -1- (4- (4- ((1- (3- (difluoromethyl) -2-fluorophenyl) ethyl) amino) -2-methyl- [1,2,4] triazolo [4',3':1,6] pyrido [2,3-d ] pyrimidin-6-yl) piperidin-1-yl) ethan-1-one
(R) -1- (4- ((1- (3- (difluoromethyl) -2-fluorophenyl) ethyl) amino) -2-methyl- [1,2,4] triazolo [4',3':1,6] pyrido [2,3-d ] pyrimidin-6-yl) -3, 6-dihydropyridin-1 (2H) -yl) ethan-1-one (30.0 mg) was dissolved in 5ml of methanol, palladium on carbon (6.00 mg) was added, one drop of acetic acid was added, hydrogen was replaced, and the mixture was stirred at room temperature overnight. After the reaction, the mixture was diluted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate for the organic phase, filtered, concentrated, and subjected to column chromatography (dichloromethane/methanol gradient elution) to obtain the title compound.
1 H NMR(400MHz,DMSO-d 6 )δ H 9.57(s,1H),8.63(d,J=7.1Hz,1H),7.99(s,1H),7.69(t,J=7.4Hz,1H),7.52(t,J=7.0Hz,1H),7.32(t,J=7.7Hz,1H),7.25(t,J=54.4Hz,1H),5.80(p,J=7.0Hz,1H),4.67-4.64(m,1H),4.04-4.01(m,1H),3.49-3.38(m,1H),3.30-3.23(m,1H),2.74-2.64(m,1H),2.44(s,3H),2.15-2.00(m,5H),1.86-1.72(m,2H),1.63(d,J=7.0Hz,3H).
LC/MS(m/z,MH + ):498.
Experimental example 1 Effect of Compounds of the invention on the p-ERK pathway in H358 cells
The effect of the compounds of the invention on the p-ERK pathway of H358 cells was assessed by the Advanced phosphor-ERK (Thr 202/Tyr 204) cellular kit method.
The experimental methods are summarized as follows:
h358 cells (ATCC, CRL-5807) containing 10% FBS (fetal bovine serum) (Gibco, 10100147) and 100U/mL of complete medium RPMI1640 (ThermoFisher, A1049101) of a mixed solution of penicillin and streptomycin (Gibco, 15140163) were cultured, and when the coverage of the cells in the culture vessel reached 80-90%, the cells were blown out and seeded in a 96-well plate (Corning, 3599) with 50000 cells per well (90. Mu.L of complete medium RPMI 1640), left to stand for 5 minutes, placed at 37 ℃ and 5 CO for 5 minutes 2 The cells were cultured in the incubator of (1) for 6 hours, and then starved overnight with serum-free RPMI 1640.
After overnight, 10. Mu.L of the diluted compound was added to each well using a line gun, and the 96-well plate was incubated at 37 ℃ and 5% CO 2 The culture box of (2) for 1h. The supernatant was decanted and washed once with PBS buffer, 50. Mu.L of lysate (Advanced phosphor-ERK (Thr 202/Tyr 204) cellular kit,64 AERPEH) was added to each well, shaken at 450rpm for 1h at room temperature, after the cells were completely lysed, 16. Mu.L of supernatant was added to 384 wells (PE, 6007299), mixed antibody (d 2/Eu = 1), incubated for 4h at room temperature, the microplate reader selected HTRF read plates, ratio = Signal 665nm/Signal 620nm x 10, and Ratio = Signal 665nm/Signal 620nm x 10 4 . In this experiment, the cell-free group (replaced with 1640 medium) was used as the 100% inhibition group, and the cell-free but compound-free group was used as the 0% inhibition group.
The percent inhibition of the H358 cell p-ERK pathway by the compound can be calculated by the following formula:
percent inhibition =100 (0% inhibition group signal value-signal value at specific concentration of test compound)/(0% inhibition group signal value-100% inhibition group signal value).
Compound IC 50 Values were calculated from 8 concentration points using XLfit (ID Business Solutions ltd., UK) software by the following formula:
Y=Bottom+(Top-Bottom)/(1+10^((logIC 50 -X)×slope factor))
wherein Y is the inhibition percentage, X is the logarithm value of the concentration of the compound to be detected, bottom is the minimum inhibition percentage, top is the maximum inhibition percentage, and slope factor is the curve slope coefficient. Fitting sigmoidal curve slope using default fitting curve to determine IC 50 The value is obtained. The results of the inhibition tests for compounds of the invention are detailed in table 1.
TABLE 1 test results for p-ERK inhibition by compounds of the present examples
Examples | IC 50 (nM) |
1 | 203 |
2 | 313 |
Experimental example 2: determination of inhibitory Activity on binding of SOS1 to KRAS G12D in examples of the present invention
The effect of the compounds of the invention on KRASG12D:: SOS1 BINDING inhibition was evaluated using KRAS-G12D/SOS1 BINDING ASSAY KITS (Cisbio, cat # 63ADK000CB21 PEH).
The experimental method comprises the following steps:
the positive control BAY-293 and test compound (10 mM stock) were diluted 5-fold to 0.1mM with 100% DMSO, and diluted 11 concentrations at 1. 0.1. Mu.L of the compound solution diluted in a gradient was transferred to 384-well plates using Echo, 2 replicates per compound, 1000rpm/min, and centrifuged for 1min. Transfer 5. Mu.L of 4X KRAS G12D (final concentration 1X) and GTP solution (final concentration 10. Mu. M, sigma, cat # V900868) to 384 reaction plates, 1000rpm/min, centrifuge for 1min, and incubate at 25 ℃ for 15min. Transfer 5. Mu.L of 4X SOS1 solution (final concentration 1X) to 384 reaction plates, 1000rpm/min, centrifuge for 1min, and incubate for 45min at 25 ℃. The final concentration of BAY-293 compound was 10,3.33,1.11,0.37,0.12,0.04,0.014,0.0046,0.0015,0.0005,0.00017,0uM. The final concentrations of the compounds to be tested were 10,3.33,1.11,0.37,0.12,0.04,0.014,0.0046,0.0015,0.0005,0.00017, and 0uM. The final concentration of DMSO was 0.5%. Transfer 10. Mu.L of 2X assay reagent solution to 384 reaction plates, 1000rpm/min, centrifuge for 1min, incubate for 180min at 4 ℃. The excitation wavelength was 665nm and the emission wavelength 615nm were read using an Envision multifunctional microplate reader. 665/615Ratio signal intensity is used to characterize the degree of activity of the enzyme.
The data processing method comprises the following steps: fitting Compound IC by Graphpad Prism 8 nonlinear regression equation 50 :
Negative control: DMSO (dimethylsulfoxide)
Positive control: 10 μ M BAY-293
The IC of the compound was obtained using the following non-linear fit equation 50 (median inhibitory concentration):
Y=Bottom+(Top-Bottom)/(1+10^((LogIC 50 -X)×HillSlope))
x log value of concentration of test compound
Y percent inhibition
Bottom is the minimum inhibition percentage, top is the maximum inhibition percentage, and HillSlope is Hill slope;
and (3) test results: under the experimental conditions, the test compound has good inhibitory activity on KRASG12D SOS1 binding. The results of the corresponding activity tests for the compounds tested are specified in table 2.
TABLE 2 test results of inhibitory Activity of Compounds of the present examples on KRAS G12D SOS1 binding
Examples | IC 50 (nM) |
1 | 5.8 |
2 | 6.2 |
Claims (13)
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof,
wherein,
x is selected from CH or N;
y is selected from CH or N;
z is selected from CH or N;
l is selected from the group consisting of a bond, NR 6 Or O;
R 6 is selected from H or C 1 -C 6 An alkyl group;
R 1 selected from H, halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 1 -C 3 Haloalkyl, C 1 -C 3 Deuterated alkyl, -O-C 1 -C 6 Alkyl or C 3 -C 6 A cycloalkyl group;
R 2 is selected from C 3 -C 10 Cycloalkyl radical, C 6 -C 10 Aryl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl, said C 3 -C 10 Cycloalkyl radical, C 6 -C 10 Aryl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 2b And/or R 2c Substitution;
R 2b independently selected from halogen, cyano, -OR 2c 、-N(R 2c ) 2 、-C(O)R 2c 、-C(O)N(R 2c ) 2 、-C(O)OR 2c 、-S(O) 2 R 2c 、-S(O) 2 N(R 2c ) 2 、-NHC(O)R 2c or-N (C) 1 -C 3 Alkyl) C (O) R 2c ;
Each R 2c Independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl, C 1 -C 6 Alkyl radical, C 3 -C 10 Cycloalkyl, C 6 -C 10 Aryl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl, said C 1 -C 6 Alkyl radical, C 3 -C 10 Cycloalkyl radical, C 6 -C 10 Aryl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted with R 2d Substitution;
R 2d selected from independently halogen, hydroxy, cyano, amino, -C (O) R 2f 、-C(O)N(R 2f ) 2 、-C(O)OR 2f 、-S(O) 2 R 2f 、-S(O) 2 N(R 2f ) 2 、-N(C 1 -C 3 Alkyl) R 2f 、-NHC(O)R 2f or-N (C) 1 -C 3 Alkyl) C (O) R 2f ;
Each R 2f Independently selected from H or C 1 -C 6 An alkyl group;
R 3 、R 4 independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl, C 1 -C 6 Alkyl or C 1 -C 3 A haloalkyl group;
R 5 selected from halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, -O- (4-7 membered heterocyclyl), -S (O) 2 -C 1 -C 3 Alkyl, -P (O) (R) 5b ) 2 、-C(O)R 5b 、-C(O)N(R 5b ) 2 、-C(O)OR 5b 、4-7 membered heterocyclic group or 5-10 membered heteroaryl group, said C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, -O- (4-7 membered heterocyclyl), -S (O) 2 -C 1 -C 3 Alkyl, 4-7 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 5a Substitution;
R 5a selected from halogen, hydroxy, cyano or amino;
each R 5b Independently selected from H or C 1 -C 6 An alkyl group;
n is selected from 0, 1,2,3 or 4;
ring A is selected from C 6 -C 10 Aryl, 5-10 membered heterocyclyl or 5-10 membered heteroaryl.
2. The compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein: r 1 Selected from H, C 1 -C 6 Alkyl or C 1 -C 3 A deuterated alkyl group.
3. The compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 or 2, wherein: r 2 Selected from 3-10 membered heterocyclyl or 5-10 membered heteroaryl, said 3-10 membered heterocyclyl or 5-10 membered heteroaryl being optionally substituted with R 2b And/or R 2c Substitution; preferably, R 2 Selected from 4-6 membered heterocyclyl or 5-6 membered heteroaryl, said 4-6 membered heterocyclyl or 5-6 membered heteroaryl optionally substituted with R 2b And/or R 2c And (4) substitution.
4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-3, wherein: r 2b Independently selected from halogen, cyano, -OR 2c 、-N(R 2c ) 2 、-C(O)R 2c 、-C(O)N(R 2c ) 2 、-C(O)OR 2c 、-NHC(O)R 2c or-N (C) 1 -C 3 Alkyl) C (O) R 2c (ii) a Preferably, R 2b Independently selected from-OR 2c 、-C(O)R 2c or-C (O) N (R) 2c ) 2 (ii) a More preferably, R 2b Independently selected from-OH, -O-CH 3 、-C(O)CH 3 、-C(O)CD 3 or-C (O) NHCH 3 。
5. The compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-4, wherein: each R 2c Independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl, C 1 -C 6 Alkyl radical, C 3 -C 10 Cycloalkyl, 3-to 10-membered heterocyclyl or 5-to 10-membered heteroaryl, or a pharmaceutically acceptable salt thereofC is 1 -C 6 Alkyl radical, C 3 -C 10 Cycloalkyl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 2d Substitution; preferably, R 2c Independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl or C 1 -C 6 Alkyl radical, said C 1 -C 6 Alkyl is optionally substituted by R 2d Substitution; more preferably, each R 2c Independently selected from H, deuterium, CD 3 Or CH 3 。
6. The compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-5, wherein: r is 3 、R 4 Independently selected from H, deuterium, C 1 -C 3 Deuterated alkyl or C 1 -C 6 An alkyl group; preferably, R 3 Selected from H or deuterium, R 4 Is selected from CH 3 Or CD 3 。
7. The compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6, wherein: r 5 Selected from halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, -O-C 1 -C 6 Alkyl, -S (O) 2 -C 1 -C 3 Alkyl, -P (O) (R) 5b ) 2 、4-7 membered heterocyclic group or 5-10 membered heteroaryl group, said C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, -O-C 1 -C 6 Alkyl, -S (O) 2 -C 1 -C 3 Alkyl, 4-7 membered heterocyclyl or 5-10 membered heteroaryl optionally substituted with R 5a Substitution; preferably, R 5 Selected from halogen, amino, C 1 -C 6 Alkyl, -S (O) 2 -C 1 -C 3 Alkyl, -P (O) (R) 5b ) 2 OrSaid C is 1 -C 6 Alkyl or-S (O) 2 -C 1 -C 3 Alkyl is optionally substituted by R 5a And (4) substitution.
8. The compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-7, wherein: n is selected from 0, 1 or 2.
9. The compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-8, wherein: ring A is selected from C 6-10 And (4) an aryl group.
10. The compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9, wherein: the compound shown in the formula (I) or pharmaceutically acceptable salt thereof is selected from the compound shown in the formula (II), the compound shown in the formula (III), the compound shown in the formula (IV), the compound shown in the formula (V) or pharmaceutically acceptable salt thereof,
wherein, ring A, L, R 1 ,R 2 ,R 3 ,R 4 ,R 5 N is as defined in any one of claims 1 to 9.
12. a pharmaceutical composition comprising a compound of formula (I) as claimed in any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
13. Use of a compound of formula (I) according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 12, for the manufacture of a medicament for the prevention or treatment of a disease associated with SOS 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021106494804 | 2021-06-10 | ||
CN202110649480 | 2021-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115466263A true CN115466263A (en) | 2022-12-13 |
Family
ID=84364240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210652494.6A Pending CN115466263A (en) | 2021-06-10 | 2022-06-09 | Tricyclic compound and use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115466263A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115677699A (en) * | 2021-07-23 | 2023-02-03 | 武汉誉祥医药科技有限公司 | Tricyclic compound, pharmaceutical composition and application thereof |
WO2023138691A1 (en) * | 2022-01-21 | 2023-07-27 | Shenzhen Ionova Life Science Co., Ltd. | Fused heterocyclic compounds as modulators of ras signalling |
-
2022
- 2022-06-09 CN CN202210652494.6A patent/CN115466263A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115677699A (en) * | 2021-07-23 | 2023-02-03 | 武汉誉祥医药科技有限公司 | Tricyclic compound, pharmaceutical composition and application thereof |
WO2023138691A1 (en) * | 2022-01-21 | 2023-07-27 | Shenzhen Ionova Life Science Co., Ltd. | Fused heterocyclic compounds as modulators of ras signalling |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2970307B1 (en) | Pyrazolo compounds and uses thereof | |
CA2798634C (en) | Pyridone and aza-pyridone compounds and methods of use | |
KR20210099611A (en) | Heteroaromatic derivative control agent, preparation method and use thereof | |
CN115466263A (en) | Tricyclic compound and use thereof | |
EP2539337A1 (en) | Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use | |
AU2015320142B2 (en) | Novel imidazopyridazine compounds and their use | |
JP2015522557A (en) | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase | |
JP7015060B2 (en) | New oxoisoquinoline derivative | |
WO2022184116A1 (en) | New sos1 inhibitor, preparation method therefor and use thereof | |
JP2019517996A (en) | 1,5-Dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one and 1,5-dihydro-4H-pyrazolo [4,3-c] pyridin-4-one as PDE1 inhibitors | |
CN117940404A (en) | Tricyclic compounds as Cbl-b inhibitors | |
WO2023198199A1 (en) | Myt1 kinase inhibitor | |
TW200524599A (en) | Substituted tricyclic heterocycles and their uses | |
CN116023378A (en) | Lactam compounds as HPK1 inhibitors and uses thereof | |
WO2022237676A1 (en) | Preparation and application of shp2 phosphatase inhibitor | |
CN113735836B (en) | Pyridazine compound and application thereof | |
CA3191529A1 (en) | Heterocyclic compounds as cbp/ep300 bromodomain inhibitors | |
WO2023051586A1 (en) | Kras g12d inhibitor compound, and preparation method therefor and use thereof | |
WO2023041049A1 (en) | Heterocyclic compound as sos1 inhibitor and uses thereof | |
JP2023527204A (en) | 3,4-dihydroisoquinoline compound and use thereof | |
CN113735837A (en) | Pyridazine compound and application thereof | |
CN111763217B (en) | Thieno-nitrogen heterocyclic compounds, preparation method and application | |
CN114315838B (en) | Pyrimidopyrroles compounds | |
RU2772226C2 (en) | New oxoisoquinoline derivatives | |
CN118684664A (en) | Benzopyrazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230807 Address after: 210032 No.99, Huakang Road, Jiangbei new district, Nanjing City, Jiangsu Province Applicant after: Nanjing Zaiming Pharmaceutical Co.,Ltd. Address before: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18 Applicant before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |